Deals in Depth: April 2009
GSK and Pfizer set up an HIV joint venture--with assets worth $373mm--that combines 17 of their drugs and compounds. GSK also made news in M&As, making a significant investment in dermatology by acquiring Stiefel Laboratories for $3.6bn. In April, device firms raised $396mm, over $100mm more than their biopharma counterparts.
You may also be interested in...
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.